Biodexa Pharmaceuticals Plc — Form 6-K Summary
Business context and reporting period
Filed October 8, 2026, this Form 6-K reports a planned change to the ratio of the Company’s American Depositary Shares (ADSs). It is not a financial-results filing.
ADS ratio change
- The ratio will change from one ADS representing 50 ordinary shares to one ADS representing 400 ordinary shares.
- The change is expected to take effect on or about October 26, 2026.
- ADS holders will exchange eight old ADSs (Old CUSIP 59564R872) for one new ADS (New CUSIP 59564R864) through a mandatory cancellation and exchange arranged by depositary JPMorgan Chase Bank, N.A.
- No fractional ADSs will be allocated. Any aggregate fractional ADSs will be sold, with net proceeds distributed to entitled holders.
- The Company describes the change as having the same effect for ADS holders as a one-for-eight reverse ADS split. The ordinary shares themselves will not be affected.
Financial performance, outlook, and risks
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or other operating-performance figures. It contains no management outlook or discussion of contingencies or unusual financial items.
Important facts for investors to verify
- Confirm the effective date and exchange instructions with the depositary or broker.
- Confirm how fractional ADS sale proceeds, if any, will be calculated and distributed.
- Note that the filing states ordinary shares are unaffected; the ratio change applies to ADSs.